LTGO
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. (LTGO) has 3 SEC Form 4 filings (23 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Aug 11, 2026.
Insiders have net bought $5.0M over the trailing 6 months. The largest single insider purchase in this window was $2.5M by 10% Owner Foresite Capital Management V, LLC on Aug 10, 2026.
Insider Buying
$5.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Foresite Capital Management V, LLCFirst filing | 10% Owner | Purchase | 140,000 | $2.5M | Aug 11 | SEC ↗ |
Tananbaum James B.First filing | Director, 10% Owner | Purchase | 140,000 | $2.5M | Aug 11 | SEC ↗ |
Related companies
Latigo Biotherapeutics, Inc. is in the Healthcare sector.